Latest On ERYTECH Pharma S.A (ERYP):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-05-14 01:17 EST | News | Erytech Pharma SA (ERYP) Q1 2023 Earnings Call Transcript | N/A |  |
| 2023-04-17 17:49 EST | News | ERYTECH receives approval to transfer its listing to Nasdaq Capital Market | N/A | |
| 2023-03-22 22:45 EST | News | Erytech Pharma reports FY results | N/A | |
| 2022-11-22 14:48 EST | News | ERYTECH Pharma S.A. (ERYP) Q3 2022 Earnings Call Transcript | N/A | |
| 2022-10-13 22:31 EST | News | ERYTECH receives non-compliance letter from Nasdaq | N/A | |
| 2022-09-13 23:56 EST | News | ERYTECH Pharma S.A. (ERYP) Q2 2022 Earnings Call Transcript | N/A | |
| 2022-08-25 07:45 EST | News | Erytech drops plans to pursue FDA approval for leukemia therapy | N/A | |
| 2022-05-17 02:15 EST | News | ERYTECH Pharma (ERYP) Investor Presentation - Slideshow | N/A | |
| 2022-05-14 09:25 EST | News | ERYTECH Pharma S.A. 2022 Q1 - Results - Earnings Call Presentation | N/A | |
| 2022-05-14 09:25 EST | News | ERYTECH Pharma S.A. (ERYP) CEO Gil Beyen on Q1 2022 Results - Earnings Call Transcript | N/A | |
| 2022-04-25 16:33 EST | News | ERYTECH divests US manufacturing facility for $44.5M and enters long-term supply pact with Catalent | N/A | |
| 2022-04-07 03:09 EST | News | British Journal of Haematology publishes positive results from Erytech's phase 2 eryaspase trial | N/A | |
| 2022-03-14 22:31 EST | News | ERYTECH Pharma S.A. 2021 Q4 - Results - Earnings Call Presentation | N/A | |
| 2022-03-14 22:31 EST | News | ERYTECH Pharma S.A. (ERYP) CEO Gil Beyen on Q4 2021 Results - Earnings Call Transcript | N/A | |
| 2022-03-14 05:56 EST | News | Erytech Pharma reports Q4 results | N/A | |
| 2022-01-24 15:50 EST | News | Erytech reports results of two eryaspase trials in pancreatic cancer at ASCO GI 2022 | N/A | |
| 2021-12-14 08:45 EST | News | Erytech Pharma launches $7.85M direct offering | N/A | |
| 2021-11-30 18:58 EST | News | Erytech jumps 32% after securing U.S. patent for methioninase & asparaginase in solid tumors | N/A | |
| 2021-11-17 10:46 EST | News | ERYTECH Pharma S.A. (ERYP) CEO Gil Beyen on Q3 2021 Results - Earnings Call Transcript | N/A | |
| 2021-11-16 14:38 EST | News | Our First Look At ERYTECH Pharma | N/A | |
| 2021-11-15 19:17 EST | News | Erytech Pharma reports Q3 results | N/A | |
| 2021-10-28 13:52 EST | News | Warning: ERYP is at high risk of performing badly | N/A | |
| 2021-10-25 11:28 EST | News | ERYTECH Pharma shares fall 32% after late-stage eryaspase pancreatic cancer trial results | N/A | |
| 2021-10-04 21:28 EST | News | ERYTECH sets maximum tolerated dose for early-stage eryaspase pancreatic cancer trial | N/A | |
| 2021-10-04 21:28 EST | News | IVAC, ERYP, CMTL and SABR among after hours movers | N/A | |
| 2021-09-30 07:38 EST | News | CNTG, APRE, LNDC and ERYP among after hours movers | N/A | |
| 2021-09-24 20:55 EST | News | ERYTECH Pharma S.A. (ERYP) Investor Presentation - Slideshow | N/A | |
| 2021-09-22 19:06 EST | News | Erytech Pharma shares fall after H1results, cash position update | N/A | |
| 2021-09-22 19:06 EST | News | ERYTECH Pharma S.A.'s (ERYP) CEO Gil Beyen On Q2 2021 Results - Earnings Call Transcript | N/A | |
| 2021-09-22 19:06 EST | News | ERYTECH Pharma S.A. 2021 Q2 - Results - Earnings Call Presentation | N/A | |
| 2021-07-30 08:16 EST | News | Erytech Pharma more than doubles after eryaspase fast track designation | N/A | |
| 2021-05-07 02:12 EST | News | ERYTECH Pharma S.A. 2021 Q1 - Results - Earnings Call Presentation | N/A | |
| 2021-05-05 10:13 EST | News | Erytech Pharma reports Q1 results | N/A | |
| 2021-03-19 00:59 EST | Analyst Rating | The Analyst Target Price has increased from $17.71 to $17.83. | Buy | |
| 2021-03-18 07:48 EST | Analyst Rating | The Analyst Target Price has decreased from $17.74 to $17.71. | Neutral | |
| 2021-03-17 19:04 EST | Analyst Rating | The Analyst Target Price has decreased from $17.79 to $17.74. | Neutral | |
| 2021-03-14 07:07 EST | Analyst Rating | The Analyst Target Price has decreased from $17.83 to $17.79. | Neutral | |
| 2021-03-12 22:54 EST | Analyst Rating | The Analyst Target Price has decreased from $17.87 to $17.83. | Neutral | |
| 2021-03-12 10:13 EST | Analyst Rating | The Analyst Target Price has increased from $17.83 to $17.87. | Buy | |
| 2021-03-10 22:44 EST | Analyst Rating | The Analyst Target Price has increased from $17.76 to $17.83. | Buy | |
| 2021-03-10 13:55 EST | Analyst Rating | The Analyst Target Price has increased from $17.68 to $17.76. | Buy | |
| 2021-03-10 06:55 EST | Financials | Company financials have been released. | Neutral | |
| 2021-03-10 06:14 EST | News | ERYTECH Pharma's (ERYP) CEO Gil Beyen on Q4 2020 Results - Earnings Call Transcript | N/A | |
| 2021-03-10 06:14 EST | News | ERYTECH Pharma S.A. 2020 Q4 - Results - Earnings Call Presentation | N/A | |
| 2021-03-09 22:51 EST | Analyst Rating | The Analyst Target Price has decreased from $17.79 to $17.68. | Neutral | |
| 2021-03-09 10:16 EST | Analyst Rating | The Analyst Target Price has increased from $17.77 to $17.79. | Buy | |
| 2021-03-07 19:46 EST | Analyst Rating | The Analyst Target Price has decreased from $17.85 to $17.77. | Neutral | |
| 2021-03-06 06:07 EST | Analyst Rating | The Analyst Target Price has decreased from $17.98 to $17.85. | Neutral | |
| 2021-03-05 22:48 EST | Analyst Rating | The Analyst Target Price has increased from $17.83 to $17.98. | Buy | |
| 2021-03-05 10:16 EST | Analyst Rating | The Analyst Target Price has decreased from $17.89 to $17.83. | Neutral | |
About ERYTECH Pharma S.A (ERYP):
ERYTECH Pharma S.A., a clinical-stage biopharmaceutical company, develops red blood cell-based therapeutics for cancer and orphan diseases in France and the United States. Its lead product candidate is eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing erymethionase, a preclinical product candidate that consists of methionine-?-lyase in red blood cells to target methionine-dependent cancers. It has research collaborations with the Fox Chase Cancer Center to advance the preclinical development of erymethionase for the treatment of homocystinuria; and Queen's University of Canada to advance the preclinical development of eryminase for the treatment of arginase-1-deficiency. The company was incorporated in 2004 and is headquartered in Lyon, France.
General
- Name ERYTECH Pharma S.A
- Symbol ERYP
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Full Time Employees 206
- Fiscal Year EndDecember
- IPO Date2016-07-05
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryBiotechnology
- Web URLhttp://www.erytech.com
View More
Valuation
- Price/Book (Most Recent Quarter) 4.95
View More
Financials
- Most Recent Quarter 2020-12-31
- Return on Assets -43%
- Return on Equity -131%
- Earnings Per Share -$2.79
- Revenue Per Share $0
- Gross Profit 3.72 million
- Quarterly Earnings Growth -40.9%
View More
Highlights
- Market Capitalization 149.69 million
- Analyst Target Price $17.83
- Book Value Per Share $10.64
View More
Share Statistics
- Shares Outstanding 21.14 million
- Shares Float 13.19 million
- % Held by Insiders <1%
- % Held by Institutions 7.05%
- Shares Short 4359
- Shares Short Prior Month 45877
- Short Ratio 0.07
View More
Technicals
- Beta 2.01
- 52 Week High $13
- 52 Week Low $3.5
- 50 Day Moving Average 9.1
- 200 Day Moving Average 8.24
View More
Dividends
- Dividend Date N/A
- ExDividend Date N/A
- Dividend Yield 0%
View More
ERYTECH Pharma S.A (ERYP) Dividend Calendar:
| Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
|---|
ERYTECH Pharma S.A (ERYP) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
| Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
|---|---|---|---|---|---|
| 2019-12-31 | 2020-03-16 | $N/A | -$1.18 | -$0.92 | -27.45% |
| 2018-12-31 | 2019-03-11 | $2.09 million | -$0.45 | -$0.60 | 25% |
ERYTECH Pharma S.A (ERYP) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date | Dec 31 2020 | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 |
|---|---|---|---|---|---|
| Research Development | N/A | N/A | N/A | N/A | 47.77 million |
| Income Before Tax | -19.75 million | N/A | N/A | N/A | -19.4 million |
| Selling General Administrative | 2.84 million | N/A | N/A | N/A | 3.26 million |
| Gross Profit | N/A | N/A | N/A | N/A | -15.22 million |
| Ebit | -20.21 million | N/A | N/A | N/A | -17.09 million |
| Operating Income | -17.33 million | N/A | N/A | N/A | -17.24 million |
| Income Tax Expense | N/A | 2000 | N/A | N/A | N/A |
| Total Revenue | N/A | N/A | N/A | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | 15.22 million |
| Total Other Income Expense Net | N/A | N/A | N/A | N/A | -6.81 million |
| Net Income From Continuing Operations | -19.75 million | N/A | N/A | N/A | -19.4 million |
| Net Income Applicable to Common Shares | N/A | -18.59 million | -17.48 million | -17.48 million | -19.4 million |
Cash Flow:
| Date | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 | Sep 30 2019 |
|---|---|---|---|---|---|
| Investments | N/A | N/A | N/A | -515000 | -1.75 million |
| Change to Liabilities | N/A | 1.52 million | 1.52 million | 1.14 million | 1.13 million |
| Total Cash Flow from Investing Activities | N/A | -566000 | -566000 | -515000 | -1.75 million |
| Net Borrowings | N/A | 1.15 million | 1.15 million | -369000 | -404000 |
| Total Cash Flow from Financial Activities | N/A | N/A | N/A | -341000 | -461000 |
| Change to Operating Activities | N/A | 11000 | 11000 | 6.73 million | 189000 |
| Change in Cash | N/A | N/A | N/A | -8.76 million | -12.52 million |
| Total Cash from Operating Activities | N/A | -14.62 million | -14.62 million | -6.63 million | -12.86 million |
| Depreciation | N/A | N/A | N/A | 2.21 million | 908000 |
| Other Cash Flow from Investing Activities | N/A | N/A | N/A | N/A | N/A |
| Change to Inventory | N/A | N/A | N/A | -187000 | 36000 |
| Change to Account Receivables | N/A | N/A | N/A | 65926.14 | 2.03 million |
| Other Cash Flow from Financing Activities | N/A | -81500 | -81500 | 28000 | -57000 |
| Change to Net Income | N/A | 67000 | 67000 | 3.89 million | -2.01 million |
| Capital Expenditures | N/A | N/A | N/A | 540000 | 1.94 million |
Balance Sheet:
| Date | Dec 31 2020 | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 |
|---|---|---|---|---|---|
| Total Liabailities | 53.86 million | N/A | N/A | N/A | 32.99 million |
| Total Stockholder Equity | 26.54 million | N/A | N/A | N/A | 85.56 million |
| Other Current Liabilities | 129000 | N/A | N/A | N/A | -1000 |
| Total Assets | 80.4 million | N/A | N/A | N/A | 118.55 million |
| Common Stock | N/A | N/A | 1.8 million | 1.8 million | 1.79 million |
| Other Current Assets | N/A | N/A | N/A | N/A | -1000 |
| Retained Earnings | -73.3 million | N/A | -34.96 million | -34.96 million | -62.66 million |
| Other Liabilities | N/A | N/A | 545000 | 545000 | 506000 |
| Other Assets | N/A | N/A | N/A | N/A | 702000 |
| Cash | 44.45 million | N/A | N/A | N/A | 73.17 million |
| Total Current Liabilities | 29.35 million | N/A | N/A | N/A | 19.88 million |
| Other Stockholder Equity | N/A | N/A | -24.04 million | -24.04 million | -135.26 million |
| Property, Plant & Equipment | N/A | N/A | 33.3 million | 33.3 million | 35.64 million |
| Total Current Assets | 49.63 million | N/A | N/A | N/A | 81.58 million |
| Long Term Investments | 17000 | N/A | N/A | N/A | 17000 |
| Net Tangible Assets | N/A | 50.43 million | 50.43 million | 50.43 million | 84.96 million |
| Short Term Investments | 8000 | N/A | N/A | N/A | 13000 |
| Long Term Debt | 14.38 million | N/A | N/A | N/A | 1.32 million |
| Inventory | N/A | N/A | N/A | N/A | 358000 |
| Accounts Payable | 4.71 million | N/A | N/A | N/A | 5.07 million |
ERYTECH Pharma S.A (ERYP) Chart:
ERYTECH Pharma S.A (ERYP) News:
Below you will find a list of latest news for ERYTECH Pharma S.A (ERYP) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
ERYTECH Pharma S.A (ERYP) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
| Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
|---|
Latest ERYP Trades:
| Date | Shares | Price |
|---|---|---|
| Jun 13, 2022 1:49 PM EST | 100 | $1.07 |
ERYTECH Pharma S.A (ERYP) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | Form Name | Link |
|---|---|---|---|
| 2020-06-26 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1624422/000119312520181121/0001193125-20-181121-index.htm |
| 2019-07-18 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1624422/000000000019011290/0000000000-19-011290-index.htm |
| 2018-07-02 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1624422/000092189518002043/0000921895-18-002043-index.htm |
| 2018-07-19 | SC 13D | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1624422/000092189518002120/0000921895-18-002120-index.htm |
| 2018-11-08 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1624422/000092189518002968/0000921895-18-002968-index.htm |
| 2020-10-13 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1624422/000092189520002591/0000921895-20-002591-index.htm |
| 2018-05-02 | F-6 POS | Post-effective amendments for immediately effective filing | https://www.sec.gov/Archives/edgar/data/1624422/000101915518000110/0001019155-18-000110-index.htm |
| 2018-07-02 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1624422/000114420418037011/0001144204-18-037011-index.htm |
| 2018-11-08 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1624422/000114420418058430/0001144204-18-058430-index.htm |
| 2018-03-12 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1624422/000119312518079452/0001193125-18-079452-index.htm |
| 2018-04-12 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1624422/000119312518114798/0001193125-18-114798-index.htm |
| 2018-04-24 | 20-F | Annual and transition report of foreign private issuers [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1624422/000119312518128812/0001193125-18-128812-index.htm |
| 2018-05-14 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1624422/000119312518162754/0001193125-18-162754-index.htm |
| 2018-05-23 | 20-F/A | Annual and transition report of foreign private issuers [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1624422/000119312518172196/0001193125-18-172196-index.htm |
| 2018-06-04 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1624422/000119312518182492/0001193125-18-182492-index.htm |
| 2018-06-07 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1624422/000119312518186183/0001193125-18-186183-index.htm |
| 2018-06-15 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1624422/000119312518193656/0001193125-18-193656-index.htm |
| 2018-06-25 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1624422/000119312518201573/0001193125-18-201573-index.htm |
| 2018-07-17 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1624422/000119312518219749/0001193125-18-219749-index.htm |
| 2019-01-04 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1624422/000119312519001992/0001193125-19-001992-index.htm |
| 2019-06-07 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1624422/000119312519168270/0001193125-19-168270-index.htm |
| 2019-06-25 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1624422/000119312519180306/0001193125-19-180306-index.htm |
| 2019-06-26 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1624422/000119312519182717/0001193125-19-182717-index.htm |
| 2019-07-16 | F-3 | Registration statement by foreign private issuers | https://www.sec.gov/Archives/edgar/data/1624422/000119312519194786/0001193125-19-194786-index.htm |
| 2019-07-16 | S-8 | Securities to be offered to employees in employee benefit plans | https://www.sec.gov/Archives/edgar/data/1624422/000119312519194796/0001193125-19-194796-index.htm |
| 2019-07-16 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1624422/000119312519194799/0001193125-19-194799-index.htm |
| 2019-07-29 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1624422/000119312519204823/0001193125-19-204823-index.htm |
| 2019-07-30 | 424B3 | Prospectus [Rule 424(b)(3)] | https://www.sec.gov/Archives/edgar/data/1624422/000119312519207053/0001193125-19-207053-index.htm |
| 2019-09-18 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1624422/000119312519247553/0001193125-19-247553-index.htm |
| 2019-09-26 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1624422/000119312519255964/0001193125-19-255964-index.htm |
| 2019-11-08 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1624422/000119312519287886/0001193125-19-287886-index.htm |
| 2020-02-06 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1624422/000119312520026789/0001193125-20-026789-index.htm |
| 2020-03-17 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1624422/000119312520076026/0001193125-20-076026-index.htm |
| 2020-04-21 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1624422/000119312520112721/0001193125-20-112721-index.htm |
| 2020-04-30 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1624422/000119312520127707/0001193125-20-127707-index.htm |
| 2020-05-08 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1624422/000119312520137551/0001193125-20-137551-index.htm |
| 2020-05-26 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1624422/000119312520151592/0001193125-20-151592-index.htm |
| 2020-06-02 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1624422/000119312520158627/0001193125-20-158627-index.htm |
| 2020-06-09 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1624422/000119312520164659/0001193125-20-164659-index.htm |
| 2020-06-25 | S-8 | Securities to be offered to employees in employee benefit plans | https://www.sec.gov/Archives/edgar/data/1624422/000119312520178939/0001193125-20-178939-index.htm |
| 2020-06-25 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1624422/000119312520179102/0001193125-20-179102-index.htm |
| 2020-06-26 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1624422/000119312520181121/0001193125-20-181121-index.htm |
| 2020-09-15 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1624422/000119312520245772/0001193125-20-245772-index.htm |
| 2020-09-21 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1624422/000119312520249553/0001193125-20-249553-index.htm |
| 2020-09-21 | F-3 | Registration statement by foreign private issuers | https://www.sec.gov/Archives/edgar/data/1624422/000119312520250299/0001193125-20-250299-index.htm |
| 2020-09-22 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1624422/000119312520250342/0001193125-20-250342-index.htm |
| 2020-10-07 | F-3/A | Registration statement by foreign private issuers | https://www.sec.gov/Archives/edgar/data/1624422/000119312520265551/0001193125-20-265551-index.htm |
| 2020-10-08 | F-3/A | Registration statement by foreign private issuers | https://www.sec.gov/Archives/edgar/data/1624422/000119312520266426/0001193125-20-266426-index.htm |
| 2020-10-09 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1624422/000119312520267325/0001193125-20-267325-index.htm |
| 2020-11-03 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1624422/000119312520284804/0001193125-20-284804-index.htm |
| 2020-11-06 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1624422/000119312520287535/0001193125-20-287535-index.htm |
| 2019-03-29 | 20-F | Annual and transition report of foreign private issuers [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1624422/000156459019010079/0001564590-19-010079-index.htm |
| 2020-03-18 | 20-F | Annual and transition report of foreign private issuers [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1624422/000156459020011602/0001564590-20-011602-index.htm |
| 2019-07-30 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/1624422/999999999519001732/9999999995-19-001732-index.htm |
| 2020-10-09 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/1624422/999999999520002806/9999999995-20-002806-index.htm |